Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 01D0987779	(X3) Date Survey Completed 05/21/2021
Name of Provider or Supplier Prattville Medical Clinic	Street Address, City, State 1739 East Main Street, Prattville, AL	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on a review of the CMS (Centers for Medicare and Medicaid) CASPER reports, a review of API (American Proficiency Institute) proficiency testing evaluations, and a telephone interview with testing personnel, the surveyor determined the laboratory failed to successfully participate in proficiency testing for Hematocrit (HCT) for two consecutive testing events. These failures resulted in an initial unsuccessful participation. This affected Event #3, 2020 and Event #1, 2021. The findings include: 1. A review of the CASPER reports revealed the laboratory scored zero percent (0 %) for HCT for Event #3, 2020, due to an untimely submission (D2127 was cited on the onsite survey, conducted on 3/9/2021); and scored 60 % for

	HCT for Event #1, 2021. These two consecutive failures of the same analyte resulted in an initial unsuccessful participation in proficiency testing. The laboratory also scored 60 % for MCH (Mean Corpuscular Hemoglobin), MCHC (Mean Corpuscular Hemoglobin Concentration) and RDW (Red Cell Distribution Width) for Event #1, 2021. 2. A review of the API testing evaluations confirmed the above noted findings. 3. In a telephone interview on May 21, 2021 at 9:30 AM, the testing personnel confirmed the testing results for Event #3, 2020, which were mailed, were not received by API by the submission date, and resulted in zero percent scores. The testing personnel also confirmed the failures of Event #1, 2021. .
D2130	HEMATOLOGY CFR(s): 493.851(f) Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on a review of the CMS CASPER reports, a review of API (American Proficiency Institute) proficiency testing evaluations, and a telephone interview with testing personnel, the surveyor determined the laboratory failed to successfully perform in proficiency testing for Hematocrit (HCT) for two consecutive testing events. These failures resulted in an initial unsuccessful participation. This affected Event #3, 2020 and Event #1, 2021. The findings include: 1. Refer to D2016.